Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 4 2Phase 3 2Phase 2 2Phase NA 1

Status

Completed 3

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Conditions

Neoplasms 1331Breast Neoplasms 687Carcinoma, Non-Small-Cell Lung 543Neoplasm Metastasis 436Lymphoma 435Leukemia, Myeloid, Acute 432Melanoma 402Prostatic Neoplasms 380Multiple Myeloma 366Lymphoma, Non-Hodgkin 356Ovarian Neoplasms 343Colorectal Neoplasms 333Precursor Cell Lymphoblastic Leukemia-Lymphoma 328Pancreatic Neoplasms 328Leukemia, Lymphocytic, Chronic, B-Cell 323Leukemia 282Lung Neoplasms 275Glioblastoma 267Unspecified Adult Solid Tumor, Protocol Specific 257Recurrence 253Lymphoma, Follicular 248Lymphoma, Large B-Cell, Diffuse 245Brain Neoplasms 232Lymphoma, Mantle-Cell 210Hodgkin Disease 193Carcinoma, Renal Cell 193Head and Neck Neoplasms 192Myelodysplastic Syndromes 187Glioma 172Burkitt Lymphoma 172

Interventions

ublituximab 1Rituximab 1LFB-R603 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × Completed × Myelitis, Transverse × Clear all
NCT02276963 2019-06-06

Ublituximab for Acute Neuromyelitis Optica (NMO) Relapses

Johns Hopkins University

Phase 1 Completed
6 enrolled 9 charts

Myelitis, Transverse, Neuromyelitis Optica, Optic Neuritis

NCT03138421 2019-01-25

Central Pain Study for ABX-1431

Abide Therapeutics

Phase 1 Completed
9 enrolled

Multiple Sclerosis, Myelitis, Transverse, Neuromyelitis Optica

NCT00501748 2011-09-27

Safety and Tolerability of Rituximab in Neuromyelitis Optica

University of California, San Francisco

Phase 1 Completed
20 enrolled

Myelitis, Transverse, Neuromyelitis Optica

Data powered by HemOnc (CC BY 4.0) Colophon âš¡